IC
KNTE

Ikarian Capital’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Ikarian Capital’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,990
Closed -$22K – 214
2022
Q1 		$22K Hold
1,990
– – ﹤0.01% 191
2021
Q4 		$35K Buy
+1,990
New +$42K 0.01% 177
2021
Q2 		– Sell
-2,000
Closed -$62K – 307
2021
Q1 		$62K Hold
2,000
– – ﹤0.01% 281
2020
Q4 		$79K Buy
+2,000
New +$80.3K ﹤0.01% 216

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital's KNTE Position: Q2 2022 in Review

Ikarian Capital sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2022, closing a stake of 1,990 shares — an estimated $22K sold.

Ikarian Capital first reported a position in KNTE in Q4 2020 and held it in 4 quarters. The position peaked at $79K in Q4 2020. 73 funds tracked by Wall St. Rank hold KNTE as of Q2 2022.

  • Ikarian Capital reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 1,990 Kinnate Biopharma Inc. Common Stock shares in Q2 2022, an estimated $22K.
  • Ikarian Capital first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Ikarian Capital's Kinnate Biopharma Inc. Common Stock position peaked at $79K in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.